Hematology Clinical Trials

Statistical methods in hematology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All hematology trials

585 results

• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (MT-3724_NHL_003): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003): primary endpoint results, effect…Phase 2Results postedn = 9NCT03645395
• Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD): Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD): primary endpoint results, effect estimate with confidence…Phase 3Results postedn = 49NCT01410227
• Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 45NCT00890929
• Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 53NCT02145403
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1/2Results postedn = 184NCT00531284
• Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 65NCT01832727
• Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 32NCT02331368
• Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00530816).Phase 2Results postedn = 164NCT00530816
• Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00588146).Phase 2Results postedn = 10NCT00588146
• Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00369681).Phase 2Results postedn = 51NCT00369681
• Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: Complete Statistical AnalysisIndependent statistical analysis of Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy: primary endpoint results, effect estimate…Phase 2Results postedn = 57NCT04140162
• Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 1Results postedn = 4NCT01743807
• Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 88NCT03583086
• Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 150NCT00506922
• Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: primary endpoint results,…Phase 1Results postedn = 66NCT04134936
• Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): Complete Statistical AnalysisIndependent statistical analysis of Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 148NCT00129740
• Phase II Study of TAK228 in Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of TAK228 in Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02727777).Phase 1/2Results postedn = 4NCT02727777
• Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 2Results postedn = 42NCT03236428
• Phase l/II Study of Ruxolitinib for Acute Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase l/II Study of Ruxolitinib for Acute Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01251965).Phase 1/2Results postedn = 27NCT01251965
• Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye: Complete Statistical AnalysisIndependent statistical analysis of Piiloset Trehalose Emulsion Eye Drop Study in Moderate or Severe Dry Eye: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 64NCT03569202
• Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 12NCT01221857
• Pilot Study for Patients With Poor Response to Deferasirox: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study for Patients With Poor Response to Deferasirox: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00749515).Phase 4Results postedn = 15NCT00749515
• Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 6NCT00901303
• Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 2Results postedn = 76NCT01338987
• Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02042924).Phase NAResults postedn = 2NCT02042924
• Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies: Complete Statistical AnalysisIndependent statistical analysis of Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04523376).Phase NAResults postedn = 8NCT04523376
• Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement: Complete Statistical AnalysisIndependent statistical analysis of Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 6NCT03724084
• Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients: Complete Statistical AnalysisIndependent statistical analysis of Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 86NCT01174446
• Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 60NCT00989664
• PIX-RIndependent statistical analysis of Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are…Phase 3Results postedn = 312NCT01321541
• PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 9NCT05380635
• Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 122NCT02872103
• Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT): Complete Statistical AnalysisIndependent statistical analysis of Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 16NCT01518153
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies: primary endpoint results,…Phase NAResults postedn = 1NCT01076270
• Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2: Complete Statistical AnalysisIndependent statistical analysis of Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 55NCT04345900
• POGOIndependent statistical analysis of Pediatric Cardiac Output Monitoring Observational Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04465370).Phase NAResults postedn = 89NCT04465370
• POLARIXIndependent statistical analysis of the POLARIX phase 3 trial evaluating polatuzumab vedotin with R-CHP versus R-CHOP in diffuse large B-cell lymphoma, including trial design, endpoints, statistical methodology, and interpretation.Phase 3n = 1,000NCT03274492
• Positive Youth Development in the Metaverse: Complete Statistical AnalysisIndependent statistical analysis of Positive Youth Development in the Metaverse: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05858593).Phase NAResults postedn = 32NCT05858593
• Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A: Complete Statistical AnalysisIndependent statistical analysis of Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 42NCT01790828
• Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis: Complete Statistical AnalysisIndependent statistical analysis of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 28NCT01860170
• Prasugrel Versus Placebo in Adult Sickle Cell Disease: Complete Statistical AnalysisIndependent statistical analysis of Prasugrel Versus Placebo in Adult Sickle Cell Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01167023).Phase 2Results postedn = 62NCT01167023
• PrE1003Independent statistical analysis of Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 1/2Results postedn = 63NCT00790842
• PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin: Complete Statistical AnalysisIndependent statistical analysis of PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 758NCT00332202
• Preventing Sickle Cell Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Preventing Sickle Cell Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02373241).Phase 2Results postedn = 1NCT02373241
• Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation: Complete Statistical AnalysisIndependent statistical analysis of Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 1,084NCT00684307
• Priapism in Boys and Men With Sickle Cell Disease – Demographics, Characteristics and Prevalence: Complete Statistical AnalysisIndependent statistical analysis of Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 1,464NCT00300235
• ProFEIBAIndependent statistical analysis of Efficacy Study of Activated Prothrombin Complex for Prevention of Bleeds in Hemophilia A With Inhibitors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2/3Results postedn = 34NCT00221195
• PROPELIndependent statistical analysis of BAX 855 PK-guided Dosing: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02585960).Phase 3Results postedn = 135NCT02585960
• Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A: Complete Statistical AnalysisIndependent statistical analysis of Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 82NCT00243386
• Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service: Complete Statistical AnalysisIndependent statistical analysis of Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 51NCT02392104

← All therapeutic areas